Cargando…

MBRS-04. MEDULLOBLASTOMA DETECTION BY BLOOD TEST

INTRODUCTION: Long non coding RNAs (lincRNAs) are functionally defined as transcripts longer than 200 nucleotides in length with no protein coding potential. lincRNA involvement in human cancers etiology is being increasingly proved. Cancer-secreted long non-coding RNAs (lncRNAs) in exosomes are eme...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yalon, Michal, Toren, Amos, Freedman, Shany, Remke, Marc, Meharian-Shai, Ruty
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Medulloblastoma (Research)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715768/ http://dx.doi.org/10.1093/neuonc/noaa222.525

Ejemplares similares

MBRS-48. IDENTIFICATION OF NOVEL THERAPEUTIC APPROACHES FOR MYC-DRIVEN MEDULLOBLASTOMA
por: Taban, Kübra, et al.
Publicado: (2020)

MBRS-64. STUDY OF ARGININE METHYL TRANSFERASES IN MEDULLOBLASTOMA
por: Cheng, Donghang, et al.
Publicado: (2020)

MBRS-22. SIGNIFICANCE OF RNF213 IN TUMORGENICITY OF MEDULLOBLASTOMA
por: Mineharu, Yohei, et al.
Publicado: (2020)

MBRS-53. CONTROL OF MEDULLOBLASTOMA VASCULATURE BY A REGULATOR OF NEUROGENESIS
por: Shaik, Shavali, et al.
Publicado: (2020)

MBRS-10. QUIESCENT SOX9-POSITIVE CELLS BEHIND MYC DRIVEN MEDULLOBLASTOMA RECURRENCE
por: Bolin, Sara, et al.
Publicado: (2020)

MBRS-01. DISSECTING REGULATORS OF THE ABERRANT POST-TRANSCRIPTIONAL LANDSCAPE IN MYC-AMPLIFIED GROUP 3 MEDULLOBLASTOMA
por: Kameda-Smith, Michelle, et al.
Publicado: (2020)

MBRS-70. FUNCTIONAL DEPENDENCY BETWEEN REST AND DNMT1 IN MEDULLOBLASTOMA
por: Maegawa, Shinji, et al.
Publicado: (2020)

MBRS-23. SIGNIFICANCE OF mi-R33 IN GENERATION AND PROGRESSION OF MEDULLOBLASTOMA
por: Matsui, Yasuzumi
Publicado: (2020)

MBRS-38. MOLECULAR CLASSIFICATION AND CLINICAL CHARACTERISTICS OF 236 MEDULLOBLASTOMAS IN JAPAN
por: Kanemura, Yonehiro, et al.
Publicado: (2020)

MBRS-17. EXAMINING THE ROLE OF LHX9 IN GROUP 3 MEDULLOBLASTOMA
por: Injac, Sarah, et al.
Publicado: (2020)

MBRS-37. RECURRENT ACTIVATING MUTATIONS OF AKT GENES IN WNT-ACTIVATED MEDULLOBLASTOMAS
por: Masliah-Planchon, Julien, et al.
Publicado: (2020)

MBRS-63. THE ROLE OF THE SWI/SNF COMPLEX SUBUNIT SMARCD3 IN MEDULLOBLASTOMA
por: Poore, Brad, et al.
Publicado: (2020)

MBRS-45. TWIST1 AND ABCB1 ARE FUNCTIONAL DETERMINANTS OF METASTASIS IN MEDULLOBLASTOMA
por: Cardall, Alice, et al.
Publicado: (2020)

MBRS-32. TOPOISOMERASE II β INDUCES NEURONAL, BUT NOT GLIAL, DIFFERENTIATION IN MEDULLOBLASTOMA
por: Miyahara, Hiroaki, et al.
Publicado: (2020)

MBRS-02. BET BROMODOMAIN PROTEIN-KINASE INHIBITOR COMBINATIONS FOR THE TREATMENT OF MEDULLOBLASTOMA
por: Ayad, Nagi, et al.
Publicado: (2020)

MBRS-27. EXOSOMES CARRY DISTINCT miRNAs THAT DRIVE MEDULLOBLASTOMA PROGRESSION
por: Jackson, Hannah K, et al.
Publicado: (2020)

MBRS-67. ROLE OF CYCLIN DEPENDENT KINASE-9 IN Myc-ENHANCED MEDULLOBLASTOMA
por: Madhavan, Krishna, et al.
Publicado: (2020)

MBRS-42. YB-1 - A NOVEL THERAPEUTIC TARGET IN HIGH-RISK MEDULLOBLASTOMA?
por: Taylor, Louisa, et al.
Publicado: (2020)

MBRS-18. TUMOR SUPPRESSOR p53 DEFINES THE THERAPEUTIC RESPONSES IN TREATMENT OF MEDULLOBLASTOMA
por: Mohan, Avinash L, et al.
Publicado: (2020)

MBRS-47. RAPID MOLECULAR SUBGROUPING OF MEDULLOBLASTOMA BASED ON DNA METHYLATION BY NANOPORE SEQUENCING
por: Masliah-Planchon, Julien, et al.
Publicado: (2020)

MBRS-06. Gli3 INDUCES NEURONAL DIFFERENTIATION IN WNT- AND SHH- ACTIVATED MEDULLOBLASTOMA
por: Natsumeda, Manabu, et al.
Publicado: (2020)

MBRS-57. IDENTIFICATION OF MYC-DEPENDENT THERAPEUTIC VULNERABILITIES FOR TARGETING GROUP 3 MEDULLOBLASTOMA
por: Llargués-Sistac, Gemma, et al.
Publicado: (2020)

HGG-04. ZINC ENHANCES TEMOZOLOMIDE CYTOTOXICITY IN PEDIATRIC GLIOBLASTOMA MULTIFORME MODEL SYSTEM
por: Toren, Amos, et al.
Publicado: (2020)

MBRS-31. COMBINING IRRADIATION AND ANTI-CD47 TO ENHANCE THE TREATMENT OF GROUP 3 MEDULLOBLASTOMA
por: Youssef, Osama, et al.
Publicado: (2020)

MBRS-28. EXOSOMES DRIVE MEDULLOBLASTOMA METASTASIS IN A MMP2 AND EMMPRIN DEPENDENT MANNER
por: Jackson, Hannah K, et al.
Publicado: (2020)

MBRS-19. SYNERGISM OF HDAC AND PARP INHIBITORS IN MYC-DRIVEN GROUP 3 MEDULLOBLASTOMA CELLS
por: Vollmer, Johanna, et al.
Publicado: (2020)

MBRS-13. MiR-1253 POTENTIATES CISPLATIN RESPONSE IN PEDIATRIC MEDULLOBLASTOMA BY REGULATING FERROPTOSIS
por: Kanchan, Ranjana K, et al.
Publicado: (2020)

MBRS-39. MAP4K4 CONTROLS PRO-INVASIVE SIGNALING IN MEDULLOBLASTOMA CELLS
por: Migliavacca, Jessica, et al.
Publicado: (2020)

MBRS-60. THE ACTIONABLE GENOMIC LANDSCAPE OF RELAPSED MEDULLOBLASTOMA IS DEFINED BY MAINTENANCE AND ACQUISITION OF DRIVER EVENTS
por: Richardson, Stacey, et al.
Publicado: (2020)

MBRS-21. CLINICAL AGGRESSIVENESS OF TP53-WILD TYPE SONIC HEDGEHOG MEDULLOBLASTOMA WITH MYCN AMPLIFICATION
por: Mitani, Yuichi, et al.
Publicado: (2020)

MBRS-14. INTEGRATING CLINICAL AND GENOMIC CHARACTERISTICS IN PEDIATRIC MEDULLOBLASTOMA SUBTYPES IN A SINGLE COHORT IN TAIWAN
por: Wu, Kuo-Sheng, et al.
Publicado: (2020)

MBRS-68. SINGLE NUCLEUS RNA-SEQUENCING DECIPHERS INTRATUMORAL HETEROGENEITY IN MEDULLOBLASTOMA WITH EXTENSIVE NODULARITY (MBEN)
por: Ghasemi, David N, et al.
Publicado: (2020)

MBRS-43. ELUCIDATING HOW NOVEL EXTRACELLULAR MATRIX SUBTYPES DIFFERENTIALLY IMPACT THE SURVIVAL OF MEDULLOBLASTOMA SUBGROUPS
por: Johnson, James, et al.
Publicado: (2020)

MBRS-24. FUNCTIONAL CHARACTERIZATION OF IKBKAP/ELP1 AS A NOVEL SHH MEDULLOBLASTOMA PREDISPOSITION GENE
por: Lopez, Jesus Garcia, et al.
Publicado: (2020)

MBRS-29. PROSPECTIVE MOLECULAR PROFILING IN PEDIATRIC MEDULLOBLASTOMA PATIENTS ENROLLED ON THE “HEAD START 4” PROTOCOL
por: Fleming, Jessica, et al.
Publicado: (2020)

MBRS-12. A TRANSPOSON MUTAGENESIS SCREEN IDENTIFIES Rreb1 AS A DRIVER FOR GROUP 3 MEDULLOBLASTOMA
por: Masihi, Meher Beigi, et al.
Publicado: (2020)

MBRS-20. CSF-DERIVED CIRCULATING TUMOR DNA AS A BIOMARKER FOR DISEASE PROGRESSION AND TUMOR EVOLUTION IN MEDULLOBLASTOMA
por: Liu, Anthony Pak-Yin, et al.
Publicado: (2020)

MBRS-66. COST-EFFECTIVE METHOD TO INCORPORATE MOLECULAR CLASSIFICATION OF MEDULLOBLASTOMA INTO A LATIN-AMERICAN CLINICAL TRIAL
por: Epelman, Sidnei, et al.
Publicado: (2020)

MBRS-46. CHARTING NEOPLASTIC AND IMMUNE CELL HETEROGENEITY IN HUMAN AND GEM MODELS OF MEDULLOBLASTOMA USING scRNAseq
por: Donson, Andrew, et al.
Publicado: (2020)

MBRS-61. MOLECULAR SUB-GROUPING OF PEDIATRIC MEDULLOBLASTOMA: CORRELATION WITH CLINICAL AND HISTOLOGICAL FEATURES, A SINGLE INSTITUTIONAL STUDY
por: Deshpande, Gauri, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cd2k12s89f7um421mlmotvq976